Ticker Details
Summit Therapeutics Inc. Common Stock Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.
IPO Date:	April 1, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$12.9B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.29 | 3.81%
Avg Daily Range (30 D):	$0.71 | 3.50%
Avg Daily Range (90 D):	$0.53 | 2.99%

Institutional Daily Volume
Avg Daily Volume:	1.09M
Avg Daily Volume (30 D):	4.24M
Avg Daily Volume (90 D):	2.88M

Trade Size
Avg Trade Size (Sh.):	135
Avg Trade Size (Sh.) (30 D):	90
Avg Trade Size (Sh.) (90 D):	81

Institutional Trades
Total Institutional Trades:	1,641
Avg Institutional Trade:	$3.16M
Avg Institutional Trade (30 D):	$2.59M
Avg Institutional Trade (90 D):	$2.97M
Avg Institutional Trade Volume:	.2M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.6M
Avg Closing Trade (30 D):	$7.29M
Avg Closing Trade (90 D):	$6.26M
Avg Closing Volume:	375.41K

News

May 23, 2026 @ 10:13 PM Why a Biotech Fund Opened a New $6 Million Positio... Source: Jonathan Ponciano

May 3, 2026 @ 1:16 PM Roblox, Spotify, And Robinhood Are Among Top 10 La... Source: Nabaparna Bhattacharya

May 1, 2026 @ 5:11 PM Stock Market Today: Apple Earnings Power S&P 500, ... Source: Piero Cingari

Apr 19, 2026 @ 2:01 PM IonQ, Oklo, And Robinhood Are Among the Top 10 Lar... Source: Nabaparna Bhattacharya

Apr 16, 2026 @ 5:06 PM Wall Street Hits New Records, Oil Surges On Hormuz... Source: Piero Cingari

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.44	$-.28	$-1.44
Diluted EPS	$-1.44	$-.28	$-1.44
Revenue
Gross Profit
Net Income / Loss	$-1079.59M	$-219.17M	$-1079.59M
Operating Income / Loss
Cost of Revenue
Net Cash Flow	$120.29M	$-13.27M	$120.29M
PE Ratio